Details Regarding Pneumonitis With High-Dose Aumolertinib

To the Editor We read with great interest the recent article by Li et al, which demonstrated the potential long-term survival benefit of high-dose aumolertinib in patients with untreated epidermal growth factor recepter (EGFR)–variant non–small cell lung cancer and brain metastases. The findings are compelling, and we commend the authors for their important contribution.